333 Lakeside Drive
8 articles about Gilead Sciences
Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults in Four-Year Data Presented at CROI
Treatment-Naïve Adults Reached and Maintained Undetectable Viral Load with Biktarvy for Certain Transmitted-Drug Resistance and with No Treatment-Emergent Resistance Through 144 Weeks
Gilead Sciences and Wake Forest University School of Divinity Partner to Address HIV Epidemic Through Faith-Based Programming and Community Outreach
Gilead Will Provide $5 Million in Grant Funding to Wake Forest Over 3 Years as Part of the Gilead COMPASS Initiative® in the Southern United States
Results from First Phase 2 Trial Describing a Triple Combination Regimen Targeting NASH Presented at The Liver Meeting Digital Experience
AbCellera, a leader in therapeutic antibody discovery from natural immune systems, announced it has entered into an agreement with Gilead Sciences to support the discovery of therapeutic antibody candidates for infectious diseases.
Hilliard & Shadowen, LLP Report Prominent AIDS Activists Join Lawsuit Challenging Anticompetitive Practices By Gilead And Other Companies
AIDS activists Gregg Gonsalves, Brenda Goodrow, Andrew Spieldenner, Peter Staley, Robert Vázquez, and Jason Walker joined with other consumers in filing an antitrust complaint in federal court in San Francisco against some of the nation's largest pharmaceutical manufacturers, including Gilead Sciences, Inc., Bristol-Myers Squibb Company, and Johnson & Johnson, Inc.'s subsidiary Janssen R&D Ireland.
Hilliard & Shadowen, LLP Report Coalition Of Consumers, Activists, And Payors Sues Gilead And Other Manufacturers For Anticompetitive Practices On HIV Medicines
A coalition of consumers, AIDS activists, and union health & welfare funds filed an antitrust complaint in federal court in San Francisco against some of the nation's largest pharmaceutical manufacturers, including Gilead Sciences, Inc., Bristol-Myers Squibb Company, and Johnson & Johnson, Inc.'s subsidiary Janssen R&D Ireland.
Gilead Sciences and Goldfinch Bio Announce Strategic Collaboration to Develop Novel Therapies for Kidney Disease
Companies to Pursue a Human Genetics Approach to Drug Discovery and Development
Funding will Expand Testing, Harm Reduction Services and Healthcare Infrastructure in States with Highest Infection Rates